Trattamento messo a punto dall’Istituto San Raffaele Telethon
Risultati per: Sviluppo di un test meno invasivo per la malattia infiammatoria intestinale
Questo è quello che abbiamo trovato per te
Blood Test Predicted Risk of Future Heart Attacks
Results from a model involving 48 proteins and 43 metabolites as well as age, sex, and systolic blood pressure might indicate that a person is at increased risk for a myocardial infarction, or heart attack, within the next 6 months, according to a cohort study involving more than 2000 people in Europe. The ability to forecast someone’s short-term risk “may enhance the motivation of patients and doctors for primary prevention,” the researchers reported in Nature Cardiovascular Research.
Covid: Girardi, oggi la malattia è totalmente diversa
Direttore scientifico Spallanzani, importante vaccinare fragili
Sviluppato un test del sangue per la diagnosi del tumore al colon
New England, prove da uno studio su 8000 individui
Sis118, test con droni pipistrello per supportare i soccorsi
Balzanelli, sperimentazione con assistenza tecnologica di Caltec
“What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
New England Journal of Medicine, Ahead of Print.
In Brasile verso test i rapidi per la Dengue. In Italia più controlli
Vaia, ‘da noi nessun allarme ma potenziamo le azioni di vigilanza’
A Next-Generation Version of the Multitarget Stool DNA Test (Cologuard)
Performance of the new version was examined in 20,000 people who were undergoing screening colonoscopy.
A Blood Test for Cancer DNA: An Eventual New Option for Colorectal Cancer Screening?
This test detected 88% of early-stage colorectal cancers but sensitivity for advanced precancerous lesions was low.
Linee guida sulla valutazione e gestione della malattia renale cronica
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening
New England Journal of Medicine, Volume 390, Issue 11, Page 984-993, March 2024.
A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
New England Journal of Medicine, Volume 390, Issue 11, Page 973-983, March 2024.
Studies to Test How Well PREVENT Predicts Heart Disease in Diverse Groups
Researchers have begun studying how accurately a new tool, known as the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator, estimates risk in people from different racial and ethnic backgrounds as well as from a range of ages, the American Heart Association announced. Three research teams will evaluate the new scores using larger databases and will assess PREVENT’s fairness and cost-effectiveness compared with the Pooled Cohort Equations (PCEs).
Malattia renale cronica, colpito il 10% della popolazione mondiale
Esperta,’spesso asintomatica. Prevenzione con test sangue-urine’. Il 14 marzo la Giornata mondiale
Sale l’allerta Dengue negli aeroporti: test ai passeggeri in arrivo dai Paesi a rischio
Una nuova circolare a quasi un mese dalla prima diffusa dalla direzione della Prevenzione del ministero della Salute
Using reference equations to standardise incremental shuttle walk test performance in children and young people with chronic conditions and facilitate the evaluation of exercise capacity and disease severity
Aims
The aim was to evaluate whether standardised exercise performance during the incremental shuttle walk test (ISWT) can be used to assess disease severity in children and young people (CYP) with chronic conditions, through (1) identifying the most appropriate paediatric normative reference equation for the ISWT, (2) assessing how well CYP with haemophilia and cystic fibrosis (CF) perform against the values predicted by the best fit reference equation and (3) evaluating the association between standardised ISWT performance and disease severity.
Methods
A cross-sectional analysis was carried out using existing data from two independent studies (2018–2019) at paediatric hospitals in London,UK. CYP with haemophilia (n=35) and CF (n=134) aged 5–18 years were included. Published reference equations for standardising ISWT were evaluated through a comparison of populations, and Bland-Altman analysis was used to assess the level of agreement between distances predicted by each equation. Associations between ISWT and disease severity were assessed with linear regression.
Results
Three relevant reference equations were identified for the ISWT that standardised performance based on age, sex and body mass index (Vardhan, Lanza, Pinho). A systematic proportional bias of standardised ISWT was observed in all equations, most pronounced with Vardhan and Lanza; the male Pinho equation was identified as most appropriate. On average, CYP with CF and haemophilia performed worse than predicted by the Pihno equation, although the range was wide. Standardised ISWT, and not ISWT distance alone, was significantly associated with forced expiratory volume in 1 s in CYP with CF. Standardised ISWT in CYP with haemophilia was slightly associated with haemophilia joint health score, but this was not significant.
Conclusions
ISWT performance may be useful in a clinic to identify those with worsening disease, but only when performance is standardised against a healthy reference population. The development of validated global reference equations is necessary for more robust assessment.